Clinical Trial Search

Primary: Posterior Probability That the Response Rate is Greater Than 50% — 1; 0.9997 Posterior Probability

Primary: Reduction From Baseline in Carotid-femoral Pulse Wave Velocity at 8 Weeks — -1.4 m/s

Primary: Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT — 55; 4; 19; 62 Participants

Primary: Change in Cellular Infiltrates From Day 0 to Day 28 — 2; 0; 2; 4 Participants

Primary: Pre-epidural Warm Sensation Quantitative Sensory Testing (QST) Results — 2.68; 5.67 Degrees Celsius — p=.04

Primary: Percent Change of Triiodthyronine Over Baseline — -3.3; -6.1 percent change

Primary: Primary Assisted Patency — 91 Participants — p=<0.0001

Primary: All-cause Mortality Rate — 1.7 percentage of participants

Primary: Weight Change — 285.0; 245.3; 273.4; 228.4 pounds (lbs)

Primary: Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1…

Primary: Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I) — 400; 400 mg

Primary: Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane) — -11.90; -1.06; -12.37; -11.14 mg

Primary: Intra- and Post-operative Pain Relief — 0.34; 0.26; 0.38 mg/kg

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 4; 4; 4; 0 Participants

Primary: Change in Montgomery and Asberg Depression Rating Scale (MADRS) — 3.20; 5.77; 4.83 units on a scale